TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Let's discuss these factors in detail to understand how to play TEVA stock at present.
TEVA's New Branded Drugs Driving Growth
The company is seeing continued market share growth of its two newest branded drugs, Austedo and Ajovy. Though Teva is seeing slightly slower growth of Ajovy in the U.S. market, it expects sales to benefit from continued patient growth and launches in additional countries in Europe and international markets.
For Austedo, Teva expects to achieve annual revenues of more than $2.5 billion by 2027. The Austedo franchise got a boost from the launch of Austedo XR, a new once-daily formulation of Austedo. Teva expects to launch Austedo in European markets in 2026.
Uzedy (risperidone) extended-release injectable suspension, a long-acting subcutaneous atypical antipsychotic injection for the treatment of schizophrenia in adults, was launched in May 2023 in the United States. In 2025, Uzedy sales are expected to be approximately $160 million.
The company has also made decent progress with its branded pipeline, which includes olanzapine, a long-acting subcutaneous injectable (LAI) for treating schizophrenia and duvakitug, its anti-TL1A therapy for inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD). Teva has partnered with Sanofi SNY for duvakitug to maximize the value of the asset. Teva and Sanofi will equally share the development costs globally. Teva's partner, Sanofi, plans to advance duvakitug, into phase III trials for both UC and CD in the fourth quarter of 2025. The company expects to file a new drug application to seek approval for olanzapine in the second half.
Teva anticipates generating more than $5 billion in revenues from its branded products by 2030.
TEVA's Strengthening Generics and Biosimilar Pipeline
Over the past few quarters, Teva has successfully launched several biosimilars and other high-value complex generics, including Novo Nordisk's Victoza, Roche's cancer drugs Rituxan (Truxima) and Herceptin (Herzuma), AbbVie's Humira (Simlandi), J&J's JNJ Stelara (Selarsdi), Novartis' Sandostatin LAR and AstraZeneca's Soliris (Epysqli).
Teva has a decent pipeline of biosimilars, with some being developed in partnership with Alvotech, including high-value complex generics like Simlandi and Selarsdi. These are the first two biosimilars to be launched in the United States under the Teva and Alvotech strategic partnership, which includes five biosimilars.
TEVA expects to launch seven (including Simlandi and Selarsdi) biosimilars in the United States and four in Europe between 2025 and 2027. Biosimilar versions of Amgen 's AMGN Prolia, Regeneron's Eylea and J&J's Simponi are under review in the United States, and those of Amgen's Xgeva, Simponi and Prolia are under review in the EU. A biosimilar of Novartis' Xolair is in late-stage development.
Teva's U.S. generics/biosimilars business looks stable now, much more than it has been in years. Its U.S. generics/biosimilars business rose 15% in the United States in 2024, driven by new product launches. Teva expects continued growth in its U.S. generics business in 2025, driven by complex product launches like Victoza, Forteo and others, as well as upcoming launches of Symbicort, Saxenda and biosimilars Simlandi and Selarsdi.
The company aims to double its global biosimilars sales by 2027 from approximately $400 million in 2024, supported by five product launches expected by then.
TEVA's Price, Valuation & Estimate Discussion
Teva stock has lost 25% so far this year compared with the industry 's 9.5% decline.
TEVA Stock Underperforms Industry YTD
The stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company shares currently trade at 6.30 on a forward 12-month basis, lower than 10.17 for the industry. However, the stock is trading above its 5-year mean of 4.11.
TEVA Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for earnings has declined from $2.56 per share to $2.51 for 2025 but risen from $2.66 to $2.72 for 2026 over the past 60 days.
TEVA's Estimate Movement
Stay Invested in Teva's Stock
Teva's revenues have suffered significantly since it lost exclusivity for key multiple sclerosis medicine, Copaxone, in 2015. The company also faces competitive pressure for some of its key branded drugs. It also has a high debt load and faces some price-fixing charges. The company may face a revenue cliff for lenalidomide capsules (the generic version of Bristol-Myers' Revlimid) in 2026, as well as headwinds in 2027 related to the IRA Medicare Part D negotiation for Austedo.
However, its newer drugs, Austedo, Uzedy and Ajovy, and stable generics business are reviving top-line growth.
With the nationwide settlement of the costly opioid litigations, new product launches, stability in the generics segment with contributions from biosimilars, and a robust pipeline of biosimilars and branded products, the path for Teva's long-term growth is becoming clearer. The company is saving costs and improving margins through the optimization of operations for efficiency while also lowering thedebt on its balance sheet. Teva expects an adjusted operating margin of 30% by 2027 through cost savings and the continued growth of its branded drugs.
In the past few months, Fitch, Moody's and S&P have upgraded their respective credit outlook for Teva, reflecting improved growth prospects.
TEVA'simproving branded and biosimilar pipeline and the prospect of growth in sales and profits are good enough reasons to stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 minutes ago
- Globe and Mail
WORKHORSE GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Workhorse Group Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Workhorse Group Inc. (NasdaqCM: WKHS) and Motiv Electric Trucks. Upon completion of the proposed transaction, Workhorse shareholders will own approximately 26.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Workhorse shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Globe and Mail
10 minutes ago
- Globe and Mail
Trump criticizes Powell again, says Fed chair is ‘hurting' the housing industry
President Donald Trump said on Tuesday that Federal Reserve Chair Jerome Powell is 'hurting' the housing industry 'very badly' and repeated his call for a big cut to U.S. interest rates. 'Could somebody please inform Jerome 'Too Late' Powell that he is hurting the Housing Industry, very badly? People can't get a Mortgage because of him. There is no Inflation, and every sign is pointing to a major Rate Cut,' Trump wrote on Truth Social. Inflation is well off the highs seen during the pandemic, but some recent data has given a mixed picture and inflation continues to track above the Fed's 2 per cent target range. Trump's latest salvo against Powell comes ahead of the Fed chair's Friday speech at the annual Jackson Hole central banking symposium, where investors will cleave to his every word for hints on his economic outlook and the likelihood of a coming reduction to short-term borrowing costs. The Fed's next policy meeting will be held on September 16-17. Investors and economists are betting the Fed will cut rates by a quarter of a percentage point next month with perhaps another reduction of similar size to come later in the year, far less than the several percentage points that Trump has called for. Trump's Treasury secretary, Scott Bessent, has promoted the idea of a half-point rate cut in September. Trump considering 'major lawsuit' against Fed's Powell over Washington headquarter renovations The U.S. central bank cut its policy rate half a percentage point last September, just before the presidential election, and trimmed it another half of a percentage point in the two months immediately following Trump's electoral victory, but has held it steady in the 4.25 per cent to 4.50 per cent range for all of this year. Fed policymakers have worried that Trump's tariffs could reignite inflation and also felt the labor market was strong enough not to require a boost from lower borrowing costs. The Consumer Price Index rose 0.2 per cent in July, with the 12-month rate through July at 2.7 per cent, unchanged from June. Core CPI, which strips out the volatile food and energy components, increased 3.1 per cent year-over-year in July. Based in part on that data, economists estimated the core Personal Consumption Expenditures Price Index rose 0.3 per cent in July. That would raise the year-on-year increase to 3 per cent in July. The PCE is a key measure tracked by the Fed against its own 2 per cent inflation target. And despite a moderate rise in overall consumer prices in July, producer and import prices jumped, a suggestion that higher consumer prices could be coming as sellers pass higher costs onto households. The inflation picture comes amid a picture of a possible cooling in the labor market, with declines in monthly job gains, although the unemployment rate, at 4.2 per cent, remains low by historical standards. Fed expected to stick with regular-sized rate cut after hot inflation data Trump's online attacks on the Fed and Powell more typically focus on the cost that higher interest rates mean for U.S. government borrowing. High mortgage rates are a key pain point for potential homebuyers who are also facing high and rising home prices due to a dearth of housing supply. Mortgage rates can be loosely tied to the Fed's overnight benchmark rate but more closely track the yield on the 10-year Treasury note, which typically rises and falls based on investors' expectations for economic growth and inflation. A Fed rate cut does not always mean lower long-term rates – indeed after the Fed cut rates last September, mortgage rates – which had been on the decline – rose sharply. In recent weeks the most popular rate – the 30-year fixed mortgage rate – has drifted downward but – at around 6.7 per cent most recently – is still much higher than it had been before inflation took off after the pandemic shock and the Fed began its rate-hike campaign in 2022.
Globe and Mail
19 minutes ago
- Globe and Mail
California American Water Completes Acquisition of Bass Lake Water Company
California American Water announced today that it has completed its acquisition of the Bass Lake Water Company system. The purchase of the system, which serves approximately 1,000 customers, was previously approved by the California Public Utilities Commission (CPUC) and reflects California American Water's ongoing commitment to strengthening water infrastructure and enhancing service in communities around the state. 'We're thrilled to begin providing Bass Lake customers with high-quality water service,' said Kevin Tilden, President, California American Water. 'We anticipate a smooth transition of services, delivering valuable experience, expertise, and a comprehensive range of customer service programs provided by California American Water to our new customers.' California American Water will begin to provide water service to Bass Lake customers on August 19, 2025. Residents will receive additional information in the mail from California American Water within the next week to facilitate a smooth transition. Bass Lake residents will be able to take advantage of the company's customer service benefits, including its online account management portal, MyWater. Additional information is also available on a dedicated webpage, Bass Lake Water, on the company's website at 'This agreement is a win for our community,' said Steve Wetch, President of Bass Lake Water Company. 'By selling the water system to California American Water we're securing the needed expertise to successfully operate our new water treatment plant and make required infrastructure improvements to provide high-quality service. The residents of Bass Lake will benefit from these improvements for decades to come.' This is California American Water's eighth acquisition in the past five years, adding more than 13,000 new water and/or wastewater customers since 2020. About American Water American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit and join American Water on LinkedIn, Facebook, X and Instagram. California American Water, a subsidiary of American Water provides safe, clean, reliable and affordable water and wastewater services to approximately 700,000 people.
